Vinorelbine as a monotherapy in metastatic breast cancer treatment
https://doi.org/10.18027/2224-5057-2017-1-78-83
Abstract
Aim: to analyze the results of treatment with vinorelbine in patients with metastatic breast cancer (BC).
Patients and methods: There were 5943 of new cases of BC in Moscow and there were 2378 patients with IV stage of the disease. 113 patients were treated with vinorelbine as a monotherapy, 1056 had other options of chemotherapy and 1209 patients had no treatment. As a first-line therapy vinorelbine was used in 13.5% of patients, as a second-line – in 59.7% and as a third-line – in 26.8%.
Results: There were no significant difference in 1-year survival between group of treatment with vinorelbine (CI 95%; 0.25–1.0), group of other options of chemotherapy (CI 95%; 0.47–1.0) and group with no treatment (CI 95%; 0.32–0.49). But there were a clear tendency of increasing of difference between vinorelbine group and group without treatment.
Conclusion: Vinorelbine is an ef fective and well-tolerated agent in patients with metastatic BC. But randomized multicenter trials are needed to evaluate ef ficacy of vinorelbine as a
monotherapy.
Patients and methods: There were 5943 of new cases of BC in Moscow and there were 2378 patients with IV stage of the disease. 113 patients were treated with vinorelbine as a monotherapy, 1056 had other options of chemotherapy and 1209 patients had no treatment. As a first-line therapy vinorelbine was used in 13.5% of patients, as a second-line – in 59.7% and as a third-line – in 26.8%.
Results: There were no significant difference in 1-year survival between group of treatment with vinorelbine (CI 95%; 0.25–1.0), group of other options of chemotherapy (CI 95%; 0.47–1.0) and group with no treatment (CI 95%; 0.32–0.49). But there were a clear tendency of increasing of difference between vinorelbine group and group without treatment.
Conclusion: Vinorelbine is an ef fective and well-tolerated agent in patients with metastatic BC. But randomized multicenter trials are needed to evaluate ef ficacy of vinorelbine as a
monotherapy.
About the Authors
A. A. KHISAMOV
Moscow Clinical Scientific Center
Russian Federation
MD surgeon
Russian Federation
MD surgeon
M. Y. PROSTOV
«Oncoprogress Foundation
Russian Federation
medical statistician
Russian Federation
medical statistician
M. Y. BYAKHOV
Moscow Clinical Scientific Center
Russian Federation
MD, PhD, DSc, professor, chief oncologist of Moscow region, deputy-chief in oncology
Russian Federation
MD, PhD, DSc, professor, chief oncologist of Moscow region, deputy-chief in oncology
References
1. Siegel R.L., Miller K.D., Jemal A. Cancer statistics, 2016.CA Cancer J. Clin 2016;66:7–30.
2. American Cancer Society. Cancer Facts & Figures 2016.
3. (EBCTCG) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials.
4. Xu Y.C., Wang H.X., Tang L., Ma Y., Zhang F.C. Breast J. A systematic review of vinorelbine for the treatment of breast cancer. Breast J. 2013 Mar-Apr;19(2):180–8. doi: 10.1111/tbj.12071. Epub 2013 Jan 16.
5. Aapro M., Finek J. Oral vinorelbine in metastatic breast cancer: a review of current clinical trial results. Cancer Treat Rev. 2012 Apr;38(2):120–6. doi: 10.1016/j.ctrv.2011.05.005. Epub 2011 Jul 13.
6. Cardoso F., Costa A., Senkus E., Aapro M., Andr F., Barrios C.H., Bergh J., Bhattacharyya G., Biganzoli L., Cardoso M.J., Carey L., Corneliussen-James D., Curigliano G., Dieras V., El Saghir N., Eniu A., Fallowfield L., Fenech D., Francis P., Gelmon K., Gennari A., Harbeck N., Hudis C., Kaufman B., Krop I., Mayer M., Meijer H., Mertz S., Ohno S., Pagani O., Papadopoulos E., Peccatori F., Pernault-Llorca F., Piccart M.J., Pierga J.Y., Rugo H., Shockney L., Sledge G., Swain S., Thomssen C., Tutt A., Vorobiof D., Xu B., Norton L., Winer E. 3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC3). Ann Oncol. 2017 Jan 1;28(1):16–33. doi: 10.1093/annonc/mdw544.
7. Gregory R.K., Smith I.E. Vinorelbine-a clinical review. Br J. Cancer 2000;82:1907–13.
8. Toi M., Saeki T., Aogi K. et al. Late Phase II clinical study of vinorelbine monotherapy in advanced or recurrent breast cancer previously treated with anthracyclines and taxanes. Jpn. J. Clin. Oncol. 35(6), 310–315 (2005).
Review
For citations:
KHISAMOV A.A., PROSTOV M.Y., BYAKHOV M.Y. Vinorelbine as a monotherapy in metastatic breast cancer treatment. Malignant tumours. 2017;(1):78-83. (In Russ.) https://doi.org/10.18027/2224-5057-2017-1-78-83
Views:
2399
Email this article 